CD86 Gene Variants and Susceptibility to Pancreatic Cancer

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2012 Jul 24

PMID 22821131

Citations 8

Authors

Honggang Xiang

Wei Zhao

Yanping Sun

Winnie Qian

Junjie Xing

Yujia Zhou

Jun Yao

Jian Xu

Yi Wang

Houshan Yao

Zhiqian Hu

Affiliations

Soon will be listed here.

Abstract

Background: Pancreatic cancer is one of the most lethal cancers worldwide. CD86 (B7-2) is a costimulatory molecule on antigen-presenting cells and plays critical roles in tumor immunity. It has been reported that polymorphisms in CD86 gene can be involved in the development of various cancers. Here, we investigated the association of two CD86 polymorphisms, +1057G/A (rs1129055) and +2379G/C (rs17281995), with pancreatic cancer in the Chinese population.

Methods: The two polymorphisms were identified in 369 pancreatic cancer patients and 412 healthy controls using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Data were analyzed by chi-square test and adjusted for body mass index, smoking, drinking, and diabetes status.

Results: Results showed that the frequency of the +1057A allele was significantly higher in pancreatic cancer cases than in controls (59.8 vs. 52.8 %, p = 0.021). Comparison of genotype frequencies showed that +1057GA and +1057AA genotypes were significantly increased in the pancreatic cancer group (odds ratio (OR) = 1.52; 95 % confidence interval (CI), 1.09-2.38; p = 0.026; and OR = 1.90; 95 % CI, 1.21-3.01; p = 0.007). We did not find any association between the +2379G/C polymorphism and pancreatic cancer. Analysis of haplotypes indicated that the AG (+1057, +2379) haplotype was correlated with the susceptibility to this disease (p = 0.019).

Conclusions: These results suggest that the CD86 +1057G/A polymorphism and AG (+1057, +2379) haplotype are genetic risk factors for pancreatic cancer.

Citing Articles

and as a Prognostic Biomarker Correlated with Immune Infiltrates in Colorectal Cancer: Evidence from Bioinformatic Analysis.

Wang Q, Huang X, Zhou S, Ding Y, Wang H, Jiang W Int J Genomics. 2022; 2022:2723264.

PMID: 36483329 PMC: 9726255. DOI: 10.1155/2022/2723264.

PDZ Proteins SCRIB and DLG1 Regulate Myeloma Cell Surface CD86 Expression, Growth, and Survival.

Moser-Katz T, Gavile C, Barwick B, Lee K, Boise L Mol Cancer Res. 2022; 20(7):1122-1136.

PMID: 35380688 PMC: 9262820. DOI: 10.1158/1541-7786.MCR-21-0681.

A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma.

Zhang Y, Xu J, Hua J, Liu J, Liang C, Meng Q J Immunother Cancer. 2019; 7(1):233.

PMID: 31464648 PMC: 6716876. DOI: 10.1186/s40425-019-0703-0.

The Influence of Genetic Variations in the Gene on the Outcome after Allogeneic Hematopoietic Stem Cell Transplantation.

Karabon L, Markiewicz M, Chrobot K, Dzierzak-Mietla M, Pawlak-Adamska E, Partyka A J Immunol Res. 2018; 2018:3826989.

PMID: 29577049 PMC: 5821961. DOI: 10.1155/2018/3826989.

CD86 regulates myeloma cell survival.

Gavile C, Barwick B, Newman S, Neri P, Nooka A, Lonial S Blood Adv. 2018; 1(25):2307-2319.

PMID: 29296880 PMC: 5729629. DOI: 10.1182/bloodadvances.2017011601.

References

Yang M, Sun T, Zhou Y, Wang L, Liu L, Zhang X . The functional cytotoxic T lymphocyte-associated Protein 4 49G-to-A genetic variant and risk of pancreatic cancer. Cancer. 2012; 118(19):4681-6. DOI: 10.1002/cncr.27455. View

Allison J, Hurwitz A, Leach D . Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr Opin Immunol. 1995; 7(5):682-6. DOI: 10.1016/0952-7915(95)80077-8. View

Landi D, Moreno V, Guino E, Vodicka P, Pardini B, Naccarati A . Polymorphisms affecting micro-RNA regulation and associated with the risk of dietary-related cancers: a review from the literature and new evidence for a functional role of rs17281995 (CD86) and rs1051690 (INSR), previously associated with.... Mutat Res. 2010; 717(1-2):109-15. DOI: 10.1016/j.mrfmmm.2010.10.002. View

Nunes J, Truneh A, Olive D, Cantrell D . Signal transduction by CD28 costimulatory receptor on T cells. B7-1 and B7-2 regulation of tyrosine kinase adaptor molecules. J Biol Chem. 1996; 271(3):1591-8. DOI: 10.1074/jbc.271.3.1591. View

Amundadottir L, Kraft P, Stolzenberg-Solomon R, Fuchs C, Petersen G, Arslan A . Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet. 2009; 41(9):986-90. PMC: 2839871. DOI: 10.1038/ng.429. View

Waterhouse P, Penninger J, Timms E, Wakeham A, Shahinian A, Lee K . Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995; 270(5238):985-8. DOI: 10.1126/science.270.5238.985. View

Shi Y, He L . SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005; 15(2):97-8. DOI: 10.1038/sj.cr.7290272. View

Loser K, Scherer A, Krummen M, Varga G, Higuchi T, Schwarz T . An important role of CD80/CD86-CTLA-4 signaling during photocarcinogenesis in mice. J Immunol. 2005; 174(9):5298-305. DOI: 10.4049/jimmunol.174.9.5298. View

Corydon T, Haagerup A, Jensen T, Binderup H, Petersen M, Kaltoft K . A functional CD86 polymorphism associated with asthma and related allergic disorders. J Med Genet. 2007; 44(8):509-15. PMC: 2597931. DOI: 10.1136/jmg.2007.049536. View

10.

Pan X, Gao L, Liang W, Liu Y, Zhu Y, Tang M . CD86 +1057 G/A polymorphism and the risk of colorectal cancer. DNA Cell Biol. 2010; 29(7):381-6. DOI: 10.1089/dna.2009.1003. View

11.

Royal R, Levy C, Turner K, Mathur A, Hughes M, Kammula U . Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010; 33(8):828-33. PMC: 7322622. DOI: 10.1097/CJI.0b013e3181eec14c. View

12.

Salomon B, Bluestone J . Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol. 2001; 19:225-52. DOI: 10.1146/annurev.immunol.19.1.225. View

13.

Jellis C, Wang S, Rennert P, Borriello F, Sharpe A, Green N . Genomic organization of the gene coding for the costimulatory human B-lymphocyte antigen B7-2 (CD86). Immunogenetics. 1995; 42(2):85-9. DOI: 10.1007/BF00178582. View

14.

Marin L, Moya-Quiles M, Miras M, Muro M, Minguela A, Bermejo J . Evaluation of CD86 gene polymorphism at +1057 position in liver transplant recipients. Transpl Immunol. 2005; 15(1):69-74. DOI: 10.1016/j.trim.2005.04.003. View

15.

Hodge J, Abrams S, Schlom J, Kantor J . Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res. 1994; 54(21):5552-5. View

16.

Petersen G, Amundadottir L, Fuchs C, Kraft P, Stolzenberg-Solomon R, Jacobs K . A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet. 2010; 42(3):224-8. PMC: 2853179. DOI: 10.1038/ng.522. View

17.

Slavik J, Hutchcroft J, Bierer B . CD80 and CD86 are not equivalent in their ability to induce the tyrosine phosphorylation of CD28. J Biol Chem. 1999; 274(5):3116-24. DOI: 10.1074/jbc.274.5.3116. View

18.

Greenwald R, Freeman G, Sharpe A . The B7 family revisited. Annu Rev Immunol. 2005; 23:515-48. DOI: 10.1146/annurev.immunol.23.021704.115611. View

19.

Pizzoferrato E . B7-2 expression above a threshold elicits anti-tumor immunity as effective as interleukin-12 and prolongs survival in murine B-cell lymphoma. Int J Cancer. 2004; 110(1):61-9. DOI: 10.1002/ijc.20085. View

20.

Krummel M, Allison J . CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995; 182(2):459-65. PMC: 2192127. DOI: 10.1084/jem.182.2.459. View